Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00156689 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.
A Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00156689: Completed Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy, sponsored by Vanderbilt University.
NCT00156689 is a Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy that has completed, run by Vanderbilt University. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00156689, a Phase 2 study of Chronic Idiopathic Axonal Polyneuropathy, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Considering the mechanisms of action which provide efficacy in epilepsy, it is hypothesized that treatment with levetiracetam will reduce the neuronal excitability involved in neuropathic pain associated with CIAP. Thus, there is a potential for levetiracetam to bring therapeutic benefit for the subjects because of its specific mechanism of action, its safety profile and the absence of interaction with other drugs.
Conditions Studied
Interventions
- DRUG levetiracetam
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00156689 record still lists
NCT00156689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Chronic Idiopathic Axonal Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which levetiracetam is the first listed.
NCT00156689 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00156689 about?
NCT00156689 is a clinical study titled "A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.". Considering the mechanisms of action which provide efficacy in epilepsy, it is hypothesized that treatment with levetiracetam will reduce the neuronal excitability involved in neuropathic pain associated with CIAP. Thus, there is a potential for levetiracetam to bring therapeutic benefit for the sub...
What is the current status of trial NCT00156689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-08. Estimated completion is 2007-05.
What conditions does trial NCT00156689 study?
This clinical trial studies the following conditions: Chronic Idiopathic Axonal Polyneuropathy.
What interventions are being tested in trial NCT00156689?
The interventions under investigation include: levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00156689?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00156689 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00156689's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia